Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas’ Prograf “Approvable” For Use In Combination With Roche’s CellCept

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will meet with FDA to get combination therapy for prevention of kidney transplant rejection approved.

You may also be interested in...



Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On

Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.

Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On

Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1

Related Content

Topics

UsernamePublicRestriction

Register

PS065782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel